Podcast appearances and mentions of paul grand

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi opens by making a strong case for MedTech people to attend DeviceTalks West, which is happening on Oct. 16-17. Go to West.DeviceTalks.com to register. MassDevice Editor Chris Newmarker brings his Newmarker's Newsmakers – Women's Health, Philiips, Nyxoah, CMR Surgical, and Johnson & Johnson MedTech. Finally, Paul Grand, CEO of MedTech Innovator, introduces DeviceTalks listeners to the five finalists who will compete for the 2024 Early-Stage Grand Prize. The winner will be voted for at the AdvaMed annual meeting in Toronto. Thank you for listening to the DeviceTalks Weekly Podcast Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

Tom Salemi, editorial director of DeviceTalks shares his accidental yet fulfilling journey into the medtech industry. Tom reveals his passion for storytelling, building communities, and highlighting the human aspect of medical device innovation. He discusses the evolution of DeviceTalks, its focus on collaboration and education, and the importance of personal connections within the industry.    Guest links: devicetalks.com Charity supported: Feeding America Interested in being a guest on the show or have feedback to share? Email us at podcast@velentium.com.  PRODUCTION CREDITS Host: Lindsey Dinneen Editing: Marketing Wise Producer: Velentium   EPISODE TRANSCRIPT Episode 036 - Tom Salemi Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to The Leading Difference podcast. I'm your host Lindsey and I am so excited to be speaking with my guests today. Tom Salemi. Tom is the editorial director of DeviceTalks. He tells medtech stories with wonder, humor, and great respect. He hosts podcasts, conducts video interviews and organizes events, both virtual and in-person to ensure our innovative medtech ecosystem stays strong and saves lives. All right. Well, thank you so much for being here, Tom. I'm so excited to talk with you this morning. Tom Salemi: Oh, it's my pleasure. Thanks for having me. It's great to be on this other side of the podcast interview experience. Lindsey Dinneen: Yeah, absolutely. Well, I would love if you wouldn't mind starting off by sharing just a little bit about yourself and your background and how you wandered into medtech. Tom Salemi: Sure. I'm a Massachusetts native, lived here my whole life. Always was aware of the healthcare industry, but I can't say I had a long time love for it or anything like that. My parents were not doctors. I am not an engineer, nor ever could be, but I did go to journalism school. And I wasn't quite sure why, it just always appealed to me. I went to visit a newspaper once, the Boston Herald, and I fell in love with the newsroom. It just seemed like the most fun place to be in the world. So I wanted to work there for a living, but later on, I think I found out it was more, I really enjoy building communities and that's gonna, I think, develop later on. I found my way into medtech quite accidentally. I was at a local paper in Massachusetts and wanted to get a job at the Boston Business Journal 'cause I was tired of covering city council meetings and planning board meetings about the height of fences and things like that. And the only beat that was open was healthcare. And at the time, this was '97, that included all the Boston hospitals, the biotechs, and the medical device companies. So it was a lot, but it was intriguing. And, I'll say my parents at the time were older and starting to see doctors more and more. So I was like, "Well, it wouldn't be the worst thing in the world to understand that industry a bit better." So I took the job at the Business Journal and then that led to an invitation to edit a venture capital newsletter that focused again, broadly on healthcare. So, that was in '98, it's called Venture Capital and Healthcare. Very very descriptive name. And from there, I just really grew to love medtech. I mean, biotech, is of course bigger and fascinating in its own right, but I never quite understood the whole molecule thing, whereas devices, you could see what this thing did and what it looked like. And how the pump worked and why I moved the blood this way or that way. It was just I think an easier and a better story for me to tell. So that's how I wandered my way into healthcare and into medical devices. Lindsey Dinneen: Wonderful. Thank you for sharing. Well, and now with DeviceTalks, can you tell us a little bit about DeviceTalks, and maybe a little bit about what you're excited about for it for the future? Because I know there's just so much in the works and it just keeps growing and it's so exciting to watch. Tom Salemi: Yeah, no, it's been an interesting development. So I joined actually DeviceTalks in 2019. It existed prior to me. It's been around for 10 years or so. It was a sort of the events business related to the Mass Device news site. So, prior to that, I was writing for magazines, wrote for InVivo and Startup. And then decided in 2014, I was I was done with writing. I just wanted to do something different. And at the same time, the company that acquired our magazine decided they wanna lay off the editorial staff. So it was it was quite a good bit of timing for me 'cause I don't think I ever would've got off the branch without a little boot in the butt. So I started doing conferences for a smaller company, medical device conferences, and podcasts. And then the opportunity to join DeviceTalks again happened in 2019 to, to run their three meetings. Of course, 2020 came around. I joined November, 2019, four months later the world shut down and we didn't have our events. So, we pivoted and launched our podcasts and our webinars and went back to events in 2022. DeviceTalks' mission has been really focused on the people who make medical devices, who design them, who manufacture them, who get them through the regulatory process. Anyone who touches a medical device from inception to handling it to a physician to have it implanted in a patient. We try to track that whole process. We do a bit of sort of the venture capital stuff, which was where my interests were lying previously. But DeviceTalks' goal is really again, to focus on the engineers and manufacturing folks, those who were really on the front lines of making medical devices. DeviceTalks has sort of morphed over time from just an events business to our podcast business, which is not only our weekly podcast, but we're working with a lot of the major OEMs to help them tell their stories through podcasts. We're continuing to roll out new series focused on specific OEMs or specific areas. We'll have a neuro one coming out soon. We'll have a structural heart one coming out soon. And we still, the DeviceTalks Tuesdays program that we launched in May 2020, because we couldn't meet the person, we did virtual like everybody else. I thought it would be something that would go away when we went back to in person, but it's only grown. So we'll continue. We continue to do about 35 of those a year. We take a month off in August and then a few days here and there for holidays. But next year we're going to be expanding that to bring some more kind of issues and OEM oriented conversations. So people seem to have responded to the opportunities to talk about medtech all the time and to listen to medtech all the time. So, as the host of a podcast, it's a pretty great time to be producing stories like these. Lindsey Dinneen: Yeah, absolutely. Well, thanks for sharing a little bit about DeviceTalks and its trajectory. It's so exciting to see how it continues to grow and evolve over time. And yeah, it's been interesting to watch how so many companies have changed, obviously because of the pandemic, but then sometimes it's been a really interesting change where, what you thought was going to happen doesn't actually happen the way, but it's exciting. And, you just keep moving with it. So that's great. Tom Salemi: I was listening to the first podcast we did in March 2020,. Chris Newmark and I were talking about, "Well, what does this mean? Like, are we not going to go to meetings? Are we going to have these conversations online? Like digitally? That's crazy. That doesn't make any sense." And we just literally described the world today, but we were both just flabbergasted, "This is nuts. This is just not going to work." So you're right. Things are evolved quickly. Lindsey Dinneen: Yeah. Yeah. And it's great. So, you're coming at the medtech industry from a really unique perspective, and you are telling stories and sharing stories about people's, incredible devices and innovations and the journey from concept to actually producing something. And I'm curious how does that storytelling process work for you? Like how do you go about finding the hidden gems within a founder's story, and then being able to take that and really run with it so that it's not just a matter of, "Hey, this device is incredible. Look at all the shiny, cool, amazing things it does. But here's the purpose and the reason behind that, too." Tom Salemi: That's a good question. I mean, I, like you, start the podcast with the stories about the guests, 'cause I'm really intrigued by their path into medtech. 'Cause I don't think it's, we know the industry itself isn't extraordinarily sexy. It's not on the front page of the Wall Street Journal. We're not talking about, well, these stupid app names that are missing vowels and people seem to get excited about it. We're a very kind of, I don't know, low key industry, but we're the industry, the people who make these devices, are literally saving lives. So I think the guests that we talk to, you know, come to it come to this industry for a purpose. You obviously can build a very successful career for yourself. But I really do enjoy trying to find out what that why is and how it came to be, how it came to lead to a career in medtech. And then I really focused down on, we've all had those moments where we've made life decisions and we could have gone this way or that way. And we chose that way. And it worked out, but what was that? What was the thought process at that fork in the road? And why was that decision made? 'Cause I think really, I think that's something that everyone can connect with. I remember talking with Mike Mahoney, the CEO of Boston Scientific at DeviceTalks Boston last year, talking about his indecision as to whether he was going to take the job at Boston Scientific. He was obviously a senior medtech guy at J& J. Why leave J& J for Boston Scientific, which was struggling at the time? And he just told this great story of how he had hired a consultant to review the situation and to give him a recommendation. The consultant was like, "No way, man, stay at J& J, you're doing great." And he was going to interview at Boston with the intention, I think, of saying no. And then he just took a moment and walked off and just looked in a mirror and said, "Do you want to do this or not?" And he said, "Yeah, I want to do this." And he just went for it and look what happened. So, I think finding those human moments in medtech is important because, more so than tech, in other industries, I think it is a very human industry because, again, people are here for a personal reason. Many people have personal stories as to why they entered medtech. Talk to people who have lost childhood friends, when they were teenagers and that drove them to medtech, obviously the state of our parents, in my case, draws you here. I think very often there's a compassionate thread. I mean, sometimes people just, maybe they go into sales 'cause they see the cars in the parking lot of, and I think there's that and that's fine too, but I think those people also come around to, "Oh wait, this is, I can have my cake and eat it too. I can actually do some good while doing well." So, I do like to focus on the human part of our industry. And I think it's one that needs to be told more because too often it's a conversation focused on FDA approvals or recalls, and we're just talking about the machinery and not the people who make it. Lindsey Dinneen: Yes. Very well said. And I completely agree with you. I think there's, oftentimes a little bit of, because to your point, it's not sort of on the front pages every day. And I will venture to say that sometimes when it is, it's for the reasons we don't want it to be. So, so it's so important to tell these stories. And the thing is, I came in from also from an outside perspective and my background is marketing and business development, business strategy. And so when I came in, it was a whole new world as well. And one thing that I realized is from an outside perspective, sometimes there's this sort of unfair stigma about people are in it solely for the money. And honestly, It's a really hard industry to be in if that's your only goal. So I think, telling these stories about these founders and the why behind it is just so compelling. And I love being able to do that. I'm so glad that you do that all the time as well. Yeah. Tom Salemi: Yeah, no it's just, those are things that need to be reported on and focused on more, so I'm glad we're both shining a light on it. Lindsey Dinneen: Yeah, absolutely. So, okay. So I know that DeviceTalks, it has so many different facets to it. One of the really interesting things that you guys do is put on events. And I was wondering if you could speak a little bit to that process and even just there, there are a number of different industry events available, but DeviceTalks pretty special. So I was wondering if you could talk to a little bit about that element and what makes it unique. Yeah. Tom Salemi: Yeah. No. So when I joined in 2019, I came aboard to help find a direction, a different direction for the meetings to focus it more on the engineering and the device making, which was going to be challenging for me. 'Cause my, again, I really focused more on who raised series A, and who raised series B, and who's a late stage investor, and who's an early stage investor. And for me, for a long time prior, medical device coverage was just, you report on the company's financings, your report on their FDA approval. And then, I don't know, all that stuff in between and who knows what happens there. So, COVID in a way presented an opportunity because we were able to focus on the podcasts and really give me an opportunity to learn about the industry, to learn about the engineering and the manufacturing about it, but also to get to know the device companies themselves and the comms teams there. So, by the time we resumed things in 2022, it sort of afforded me the opportunity to really work with the comms teams at the big companies, and the engineers and the folks who had on podcast, and try to get those stories that we told on the podcast on stage and maybe a grander fashion. Maybe there's a PowerPoint vote. Maybe there's two or three people who can talk about pulse field ablation, who can talk about the orthopedic business, who can talk about surgical robotics. So DeviceTalks, although we include some of that in our conversations, partnership and financing, especially in Boston, we've got The Medtech Innovator there and they run a great innovation, sort of forum investment forum. I just love working with Paul Grand and I love The Medtech Innovator crowd. And I still love startups, the folks who start companies are just absolutely insane in a good way. God bless them. I love it. And so, but I really wanted to give an opportunity for the Strykers, for the Boston Scientifics, for the Medtronics to come and sit down in sort of a collegial atmosphere and say, "Look, this is, this is the device we're working on. These were the challenges we had in developing it. This is how we're looking at the patient population." And just go over different challenges that that they had overcome. So it really, I think, is an opportunity for everyone to sit down and talk about the designing, the making, even the selling. We're actually getting more into the selling of medical devices to talk about the business of medical devices in a very, almost. I don't want-- collegiate sounds weird-- but just a very educational, sort of open setting. So we'll do, we have our keynotes, we'll have our big CEO keynotes. We'll have a venture panel from time to time. And like I said, we'd love to have the startups present, especially in Boston with MedTech innovator. We do that a little less of that at DeviceTalks West, but our bread and butter can sit continues to be engineering and manufacturing. And we really want folks to come down and talk about the intricacies behind their very cool and important and lifesaving devices, so people walk away with a better understanding of how to make their life saving device. And hopefully if they've taken the time to get to know this person who's achieved something great, and maybe they connect on LinkedIn, and it leads to a company being started five or six or 10 years down the road or two or three years down the road. Who knows? So we're all about again, open conversations about medical device development and about fostering the opportunity for personal connection as well. Lindsey Dinneen: I love that. Well, and I love your focus on collaboration, and education and that, the knowledge is shareable and it's really important and I think it's really impressive that you've created an atmosphere where people do want to come and share and talk about the good, the bad, and the ugly of their process and being able to share those stories, like you said, could very well inspire the next generation of innovators because it's important to be honest and transparent when you can be. So I think that's really incredible that you've fostered this atmosphere that, that leads to that. So. Tom Salemi: No, thank you. No, and I'm really grateful to those companies that take advantage. Sometimes folks will come and maybe their presentation is a little scripted. But I think just having that person in the room, the Chief Technology Officer or the Director of Engineering for some valve program is important. And it just gives people, I think as much as-- if I were to create a pie chart for the importance of stuff that goes with a bar graph that happens on stage versus like the 10 minutes after someone's on stage, it's probably the bars are probably pretty close. I'm not sure which is more important, but I think just getting everybody together and we've actually, I initially fought this, I'll admit it, but first couple of conferences, we had like five minutes in between sessions 'cause I just wanted to pack so much in. This year, our conference team was like, "Can we do 15 minutes?" And I was like, "No!" If you add it up, you've probably lost like 30 minutes of programming, but the 15 minutes was really great for just to give people some comfortable time to like, "Hey, I heard what you said about X. Here's something I'm working on, what do you think about that?" I think that those kinds of conversations are are very important and you can lead it up. You can leave it up to serendipity that, "Oh, if I'm at the conference and the Chief Technology Officer from major medtech is going to be there, I'll bump into him in the cocktail reception," but it's not always easy to do. So we try to, we really try to foster those connections so people get the insights they need and go home with some really positive insights and feedback. Lindsey Dinneen: I love that. Yeah, I absolutely love what your company does for that. That's incredible. Tom Salemi: Thank you. Lindsey Dinneen: So along your journey, have there been any moments where it stood out to you that you had this realization that "Yes, I am in the right industry at the right time." And just something, like a story that you got to share or something that just made you go, "Oh yes, I'm in the right place here." Tom Salemi: Interesting question. I mean, I have a lot of those moments. Some of those singular moments, I think, some are a just collective moment. Like I've said before, when I was covering the Newburyport City Council, there was literally a moment where they were arguing about the distance-- I was there supposed to be covering this meeting-- and they were talking about the height of fences. And I literally got up and just left. And I was like, "I can't spend, I don't want to dedicate another minute of my life to this." And I've never done anything like that before. I am this Joe Earnest, like I'm gonna stay to the end and make sure it goes. I had the whole journalism thing going on. But I was just like, "I just can't spend my life doing this." I've never, ever had that moment in medtech. I've never come to work and said, "Why am I writing about this? Or why am I talking to this person? Or what, what is this even about? What's the point?" I've never even thought that. And I would have that conversation if I were covering insurance or even, when I was at my newsletter, got a company by Dow Jones. And I thought my only path up was really to like get into news wires and start covering earnings and things like that. And I was like, " I don't want to be covering earnings and being measured by like, did I beat AP or whomever or Bloomberg by 35 seconds?" No, that's not what I want to do. I want to write about cool tech and talk to cool people. So that's when I left Dow Jones and joined EnVivo and Startup, cause I really wanted to focus on medtech. But, there are a lot of those moments where I'm really glad to be doing what I'm doing and there's singular moments too, where, I'm sitting in a plane and I look across the aisle and the woman next to me is just reading an EnVivo Magazine and she's got my article open. And I'm like, ah, I just want to tap her in the shoulder. " What do you think? What do you think about Right Medical, huh? Pretty interesting stuff, huh?" That was very cool. I remember interviewing Kevin Lobo at the early medtech conference I did in Minnesota. It just went super well. He's a really great guy to talk to and very easy to talk to, very open and honest, and will answer any question. But just getting off the stage was like, "Wow, that was a lot of fun. I want to go up and do another one." Which is weird, 'cause I wasn't a big stage guy before, but I don't know, the opportunity to dig and find some cool stories and really see the humanity in these medical device folks is a great challenge and a great privilege for me. I'm really blessed to have the access that I have. So I'm very grateful. Lindsey Dinneen: Amazing. Oh my gosh, I loved that so much. And yeah, I totally, it would be hard not to go, "Hey, what do you think?" Tom Salemi: Exactly, right? Yeah. Then what? Then like, "Oh yeah." Then she's like, "Sure. Sure. You're Tom Salemi." And then it gets really weird. "Oh really?" I let it be, but it's one of those forks in the road moments. What would have happened if I just asked her if she liked the right medical story and maybe who knows? I don't know. Lindsey Dinneen: That's so great. Tom Salemi: I might've had, I might've met a future CEO and then had a great story to tell with her someday. So. Lindsey Dinneen: It's still a possibility. Tom Salemi: it still happen. Lindsey Dinneen: Maybe you'll run into again. Tom Salemi: She's hearing this, maybe. She's like, "Wait a minute, I did read an EnVivo Magazine on the plane once next to some weird guy who was..." Lindsey Dinneen: "...weirdly watching me while I was reading it." Tom Salemi: Exactly, while was reading a magazine. Lindsey Dinneen: That's so funny. I love it. Well, pivoting the conversation just for fun. Imagine that you were to be offered a million dollars to teach a masterclass on anything you want. It can be within your industry, but it doesn't have to be. What would you choose to teach and why? Tom Salemi: Wow. People say "that's a great question" to me all the time. And I always like, "I don't really have that many great questions. Like one or two of them are great!" But that's a good, that's a really great question. Oh, wow. I think For me, learning to speak publicly and enjoy the time on stage, I think has been a real blessing for me. So, and I know a lot of people have that ability as well. I think that would be great thing to, to share with folks. But I think moreover, I mean, it's crazy to me that like people look to me like some sort of storytelling expert where I really just like, it's like, "You're really interesting. I'm not conjuring magic. You have a great story that you just don't know exists. I'm not some wizard who's just waving my wand and saying something in broken Latin and it all happens. It's all in you." And I wish folks could look inside and see their own stories and see the stories of others as well. And they're probably too busy designing that next great device that they don't really have that ability to look inward. But, I think helping people identify their own stories, not necessarily to tell them in a podcast form, but just to have a better sense of, of who they are. I mean, I've talked to a few people who like you, I'll say, "Oh, I'll start the conversation learning about you." And they'll say, "Well, I'm boring. Just talk about the company." And I said, "You're not boring. I've never talked to a boring person." Believe me, like everyone has great stories and everyone has great decisions that they made and, it's just a matter of telling it, or at least knowing those stories are in there. So, because I can't teach on anything of technical value, I guess I'll focus on that. Just helping people identify their own stories and and sharing them in the world in a way that's appropriate for them. Again, they don't have to have a YouTube channel, but they could just say, "Hey, I do important work. I'm interesting. And, I've made a difference in the world." That's pretty awesome. Lindsey Dinneen: Yes. Well, I love that. And I actually think the wizardry component of it comes in with allowing people to feel safe enough to tell their stories, and comfortable, because it can be harder, especially when you're maybe telling a story that is challenging for you, that talks about something where maybe things didn't go the way that you hoped they would, or you failed at something. And so, so giving people, providing that safe space, basically, to allow people to share those stories and encourage it is, I think you've got that wizardry component. Tom Salemi: Oh, I appreciate that. And that's a great point. And I think, like with the keynotes, when you're talking with someone who's willing to trust you a bit and say, "Look, when I do keynotes," I'm like, "Look, these are the things I want to talk about." Just allow me to, if I hear something interesting, I go, "Wait a minute, can I just pull that thread a moment," and just to have someone trust you that you're not going to take it in a really weird way, that you're going to see the positive, I think, is when you really have done your job and have a great keynote. Those are the moments, especially like at a conference where people walk away and say, "That was great." Keynotes should be really great and interesting. They can be informative as well, but if you're just focusing on, why you designed this over that and why that, why it's important to help people with this dreadful disease, all of that's important, but I think the stories that really resonate with people are the ones when they, where the people in the audience can really form a connection with the person on stage. I think that's when you really hit the home run. So, just trying to do that. Lindsey Dinneen: Yes. Yes. Yeah, absolutely. And I think to your point, another component that you do really well and that I think is important in that sort of wizardry aspect, is the respecting and honoring of the person's choosing to tell that story. So it is, like you said, drawing out the positive and honoring the fact that they've decided to share with you. And so therefore they continue to feel safe, and respected in sharing their insights and stories and whatnot. So I think you're absolutely right that it has to have multi layer components. And, and I love your thing. You've never met a boring person. That's so great. That's so true. Tom Salemi: It's true. I mean, just talk to people. My son is going to be an engineer and he's like already 10 times smarter than I am technically. I teach him how to jump a car battery and he's explained to me, "Oh yeah, that's why the red has to be attached to the black." And I'm like, "I don't know that. I just know red and black. Don't tell me why the battery works. I don't really need to know that. I just need to know how not to set my car on fire." That's where my technical knowledge. But there are people in the world who understand how things work. And I just-- that's witchcraft. To understand, why planes fly and why batteries work. That stuff's amazing to me. Lindsey Dinneen: I agree. I agree. All right. And so, on a bit of a more serious note, how would you like to be remembered after you leave this world? Tom Salemi: Oh, wow. I mean, like I said at the start, I got into journalism cause I thought it would be fun. And I was also a shy kid and I didn't want to be in a cubicle all my life, 'cause I think, I don't think I'd ever climb out of it. I wanted to really force myself into the world. But then I came to realize that what I really liked was helping people connect and I think that's becoming harder and harder for people to do, not to get too heavy about it, but I think there are a lot of lonely people in the world who aren't finding connection or the connections they are finding aren't necessarily the most productive. So I hope, I hope I, I ease that somewhat and I'm always --just last week, actually, I got a couple of great messages and I don't get a ton of these. It's just weird timing, but someone who said that they enjoy the podcast, and they're college students, and they went into biomed because of the podcast. They joined a startup competition. It's like, "Wow. I, with my stupid stories, I had an impact on someone in a positive fashion!" And I told this person, " Great. When you invent the lifesaving technology," I said, "I will take total credit because I'm the one who stirred you into medical devices." I'm getting a few of those nice messaging, and it's, I hope that people remember that, we have a lot more in common... I hope people will think that I've reminded people that we have a lot more in common than we do differences, and that we have a lot more positivity to rally around the negativity. And it's the only way we're going to get things done in this world is if we're working together on it. So if I could help that happen a little bit, I think I'd be happy with that as a life lived. Lindsey Dinneen: Yeah. Yeah, absolutely. Wow. And thanks for sharing that story. That's incredible. That is so exciting. Tom Salemi: I'm so grateful. I told him, I'm so grateful that person wrote, "thank you so much," 'cause that, yeah, that people don't do that very frequently. So it's awesome. Lindsey Dinneen: Yeah, and final question. What is one thing that makes you smile every time you see or think about it? Tom Salemi: Huh. My first thought was my, my kids just seeing them find their way through life, seeing them find the things that energize them. It's great when you see that. Dogs, of course would be a good one. Lindsey Dinneen: Yes. Tom Salemi: I love a good dog. I don't know, everything that's coming to mind, it sounds kind of corny. I mean, obviously when you see people take a kindness on somebody else, or be kind to someone else when they don't need to be, I think is extraordinarily uplifting. So my kids, my dogs, my dog, any dog, actually most dogs will do... Lindsey Dinneen: Yes. Tom Salemi: Yeah. But my dog in particular, but no, I think I just, those moments that, unfortunately, we're not shining enough light on where people are overly kind and helpful to each other. I think we need to see more of that at this time. Lindsey Dinneen: Yeah. Agreed. Well, I think that's phenomenal. I, I also am a huge dog lover. So anytime, I mean, really, it's like an instant happiness. Tom Salemi: Yeah. Lindsey Dinneen: Instant. So happy. So. Yeah, they are the best. Well, I just want to say this has been an incredible conversation. It's been so great to get to know you a little bit and also get to know a little bit more about the incredible work that DeviceTalks is doing. So I just want to thank you so much for being here and being willing to share your stories. This has been great. Tom Salemi: Oh, thank you so much. It was an honor to be asked. It doesn't happen frequently and it was-- you've got some great questions. I may steal a couple of them. So. Lindsey Dinneen: Absolutely. Well, thank you again. We are so honored to be making a donation on your behalf as a thank you for your time today to Feeding America, which works to end hunger in the United States by partnering with food banks, food pantries, and local food programs to bring food to people facing hunger. And they also advocate for policies that create long term solutions to hunger. So thank you for choosing that organization to support and thank you for all the work you do to change lives for a better world. Tom Salemi: Okay. Thank you so much. Lindsey Dinneen: Thank you also to our listeners. And if you're feeling as inspired as I am right now, I'd love it if you would share this episode with a colleague or two, and we will catch you next time. Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

As a startup venturing into the dynamic landscape of medical technology innovation, the road ahead may seem riddled with obstacles. From fierce competition to ever-evolving regulatory landscapes, the journey to success can be fraught with uncertainty. I'm your host, Kevin Blevins. In the last episode, Jim Gernatt and I were speaking with Paul Grand founder and CEO of Med Tech Innovatory. We left off discussing Paul's background, the remarkable journey of Med Tech Innovator, and its pivotal role in shaping the future of healthcare. Today, we continue this conversation with Paul diving into innovative initiatives driving this transformative organization.  In this part, you will gain insights into the pivotal role of organizations like MedTech Innovator in guiding companies through the complexities of commercialization, including navigating investment challenges and addressing payment and coverage issues. By the end of this episode, you'll have a comprehensive understanding of the MedTech Innovator landscape and actionable advice for making a significant impact in healthcare. What You'll Learn in This Episode: Challenges faced by MedTech startups, including lack of guidance and funding. (04:16) MedTech Innovation ecosystem, including peers, key opinion leaders, investors, strategic partners, and payers. (07:02) The value of working with a partner like Siemens. (14:05) The importance of getting out of echo chambers and seeing different perspectives. (20:20) The importance of fixing investment and payment systems in the medical technology industry. (31:49) Connect with Paul Grand: LinkedIn Website  Connect with Jim Gernatt: LinkedIn Connect with Kevin Blevins: LinkedIn

Accelerators provide essential coaching, resources, mentorship, and networking opportunities to startups, enabling them to navigate challenges and scale effectively in the competitive landscape.  I'm your host, Kevin Blevins, and I have a co-host, Jim Gernatt. He leads the Innovation Partnership ecosystem for Siemens, working with incubators and accelerators.   Today, we're speaking with Paul Grand, founder and CEO of MedTech Innovator, one of the foremost MedTech accelerators globally, dedicated to fostering innovation in digital health, medical devices, and diagnostics. In this part one of a two-part episode, you will gain valuable insights into the unique challenges and opportunities faced by startups in the MedTech space. From understanding the funding dynamics and investor sentiments to the genesis of MedTech Innovator as a platform to support and guide healthcare startups, this episode offers a deep dive into the world of medical technology entrepreneurship.  What You'll Learn in This Episode: MedTech industry funding challenges and exit opportunities. (2:28) Entrepreneurship, resilience, and persistence in the MedTech industry. (7:29) The evolution of a venture capitalist in the MedTech industry. (13:17) The challenges faced by MedTech startups in gaining visibility (16:27) MedTech innovation and its impact on healthcare. (21:35) Connect with Paul Grand: LinkedIn Website Connect with Jim Gernatt: LinkedIn Connect with Kevin Blevins: LinkedIn

We'll open this week's episode with Paul Grand, CEO of the MedTech Innovator. Grand issued a last call for medical device entrepreneurs to apply to be part of this year's program. Lots of good stuff come with it. Listen to the episode and apply at MedTechInnovator.org. Then Co-Hosts Tom Salemi and Chris Newmarker interview successful startup CEO Bill Gruber about his new book, The Leadership Blueprint. Gruber shares some experiences and lessons, but entrepreneurs are encouraged to buy the book on Amazon. Finally, Tom Salemi interviews Ahmet Tezel, Company Group Chairman and Global Head of J&J MedTech Innovation and R&D about his path into medtech and what the future holds for Johnson & Johnson and the medical device industry. Thank you to the sponsor of this episode – Tecan. Here's a message - Tecan brings all the healthcare OEM pieces together with fully integrated solutions across the entire MedTech and life sciences spectrum from idea to implementation. Partner with us to revolutionize the way you develop medical technology with the Emphysys approach and turn your visionary ideas into a tangible reality in a matter of months, not years. www.emphysys.com/ Thank you for listening to the DeviceTalks Podcast Network. Subscribe now to the DeviceTalks Podcast Network.

Paul Grand is the founder and CEO; Ayelet Marom is the Program Director for BioTools Innovator, which focuses specifically on biotools; and Jim West is the Associate Director, BioTools Innovator, who was previously the Co-Founder and CEO of, Clara Biotech, which was founded in 2018 and was acquired by Innovaprep in the summer of 2023. Jim was the first founder to go through the biotools program. In this episode of lab to startup, we first discuss some of the challenges that affect medtech and biotool technology startups, and then go into ways that medtech innovator, an accelerator program is helping founders in this space, especially around lessons learned and how the program has evolved into one of the best accelerators in this space. https://medtechinnovator.org/about-us/ Founding story of Medtech Innovator Things medtech startups struggle with: Articulating value proposition; understanding reimbursement; having the wrong CEO; staying in stealth mode; choosing the wrong indication Medtech innovator “Value program” Value coaches from established companies like J&J How startups get accepted to the program No equity, no fees and no strings attached for being a part of the program Bringing the right investors to the table to support founders Biotools innovator program: https://biotoolsinnovator.org/ Challenges in the biotools space How investors are different in this space Pay for Service as a model Story of Jim West, Founder and CEO of Clara biotech, that went through the program Advice on slide decks Info session videos: https://www.youtube.com/@Medtechinnovatorchannel

This week's episode is dedicated entirely to the 10 Finalists of MedTech Innovator's Pitch Competitions. The final winners will be selected by the audience on Oct. 10 at the upcoming AdvaMed annual meeting. The finalists for MedTech Innovator's grand prize of $350,000 are listed below. Click on the link to watch their 1-minute pitch video. Dr. Tom McClellan - Fingy3D - https://www.youtube.com/watch?v=KCoj_ZALf3c Amanda French - IFPx - https://www.youtube.com/watch?v=8B3j2weOkNo Jay Shah/Vivek Ganesh - Neurava - https://www.youtube.com/watch?v=lyUB9WCLeww Dr. Alex Woods - Newrotex - https://www.youtube.com/watch?v=MEhP_Ack32c Alex Ballatori/Shane Shahrestani - StrokeDx - https://www.youtube.com/watch?v=tdkl5QyDfD8 The companies listed below are vying for MedTech Innovator's Execution Award. The winner will receive $25,000. Click on the link to watch their 1-minute pitch video. Harlee Sorkin - InterShunt Technologies - https://www.youtube.com/watch?v=QPi5FSRSjUQ Michael Ebner - Hypervision Surgical - https://www.youtube.com/watch?v=oTz-AXfwJgw Lori Arakaki - Opticyte - https://www.youtube.com/watch?v=AECmlLpv0hE Joanna Nathan - Prana Thoracic - https://www.youtube.com/watch?v=myjUp3Gg4mQ Dushyanth Surakanti - Sparta Biomedical - https://www.youtube.com/watch?v=wvS9PwpkT_c DeviceTalks's Tom Salemi and Kayleen Brown visited with the founders and CEOs of each of the 10 companies. We'll run through those interviews with Paul Grand, CEO of the MedTech Innovator program. Thanks for listening to the DeviceTalks Weekly Podcast Subscribe to the DeviceTalks Podcast Network on any major podcast application.

Last call for DeviceTalks Boston! In this episode we'll preview our upcoming conference by talking with Paul Grand, CEO of Medtech Innovator, Rebecca Whitney, SVP at ZimView, Holly Scott and Joe Mullings at the Mullings Group. We'll have Fastball Pitches from two Medtech Innovator companies that will be presenting on May 10-11. Register at DeviceTalks.com. Use the code DTWeekly25 to save 25% Chris Newmarker delivers his #newmarkernewsmakers featuring 3M, Zimmer Biomet, Stryker, Medtronic and Casana, maker of a now FDA-approved smart toilet seat. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Player on any major podcast application.

In this episode, Tom Salemi interviews Mark Dickinson, worldwide president at Cerenovus, the neurovascular business at Johnson & Johnson Medtech. Mark Dickinson shares his unique entry into the medical device industry, how he built his career at the global company, and what the company is doing to develop its devices to treat stroke patients. In addition, we'll also have interviews with Paul Grand, CEO of Medtech Innovator, and Jeff Alvarez, chief strategy officer at Moon Surgical. Both will be speaking at DeviceTalks Boston on May 10-11. Go to DeviceTalks.com to register. This episode is sponsored by the Medical Business Unit at TE Connectivity. For more information go to TE.Com/medical. Thanks for listening to this episode of the DeviceTalks Weekly Podcast. You can subscribe to the DeviceTalks Podcast Network on any major podcast application.

In this episode, Celine Martin, company group chairman, Cardiovascular & Specialty Solutions Group, offers insights from her career at Johnson & Johnson. What are the four variables you need to consider to thrive in a global company. Martin also shares insights on cardiac ablation, neurovascular, and where the company is headed following the acquisition of Abiomed. Paul Grand, CEO of Medtech Innovator, joins as a co-host offering insights on Chris Newmarker's Newsmakers – Moon Surgical, Butterfly Network, Medtronic, Avail Medsystems, Dexcom, and Fresenius Medical. Grand shares a personal connection to one of the companies. Grand, Newmarker and Tom Salemi also share their thoughts on the retirement of Mike Mussallem, CEO of Edwards Lifesciences. Thank you to Nordson Medical for sponsoring this episode. Go to NordsonMedical.com for more information. Thank you for listening to the DeviceTalks Weekly Podcast You can subscribe to this podcast on any major podcast player.

Just a short visit today. Paul Grand of the Medtech Innovator introduces us the five finalists of his start-up program. They'll compete for the top spot at AdvaMed's meeting next week. in Boston. Remember to join us at DeviceTalks West THIS week. Register at DeviceTalks.com.

We're continuing our season topic: The F Word (Fundraising) On today's episode, we welcome back host Isabella Schmitt as she speaks with Paul Grand, CEO of MedTech Innovator, one of the largest accelerator of medical technology companies in the world. Finding and selecting the right investors for your business, product, or idea can be a stressful and grueling process. There is so much vetting to do on both sides on the street that it can make it hard to focus on the big picture. Hmm... this almost sounds a little like dating. Today's episode: The Investor Dating Game.    

DeviceTalks Boston is here! Win a free registration. In this week's episode, we'll give you a little taste of what you'll see at the Boston Convention & Exhibition Center on May 10-11. Friend and colleague Steve Crowe, editorial director of the Healthcare Robotics Engineering Forum, will share what attendees will see at that meeting, which is co-located with DeviceTalks Boston. Then, we'll talk with Peter Stebbins about his Opening Keynote Interview with medtech veteran Peter Doyle, who is now dean of Harvard John A. Paulson School of Engineering and Applied Sciences. We'll also get a final update from Paul Grand, CEO of Medtech Innovator, about the 22 mid-stage medical device companies that will be presenting at DeviceTalks Boston. A selected few will then compete at Medtech Innovator's Pitch Contest on May 11. And to demonstrate we're not just selling you on an event, we talk with Dave Evans, co-founder and CEO of Fictiv, a technology company that has raised nearly $200 million to fix – or disrupt – the supply chain. Finally, a contest for loyal and attentive DeviceTalks Weekly Podcast listeners. Win free registration to DeviceTalks Boston!

In this week's podcast, we'll speak with Sally Saba, MD, Medtronic's chief inclusion and diversity officer, about the company's work to create a more welcoming – and better performing – workplace. Paul Grand, CEO of MedTech Innovator, returns to take part in Executive Editor's Chris Newmarker's Newsmaker session. We talk about hour industry's response to Russia's invasion of Ukraine, Ryan Egeland, MD, joining Big Sky Innovator, the top-performing companies of 2021, the collapse of another SPAC deal, and an eye-opening approval. https://www.medicaldesignandoutsourcing.com/how-medtech-and-pharma-are-responding-to-russias-invasion-of-ukraine/ https://www.massdevice.com/former-cardiovascular-systems-chief-medical-officer-joins-big-sky-biomedical-incubator/ https://www.massdevice.com/these-10-medtech-companies-stocks-performed-best-in-2021/ https://www.massdevice.com/memic-innovative-surgerys-spac-deal-is-off/ https://www.massdevice.com/alcon-launches-clareon-intraocular-lens-in-u-s/ BUY A MAMMOTH TOOTH FOR A GOOD CAUSE - https://www.newburyportnews.com/news/mammoth-find-for-gigantic-ukrainian-cause/article_bed30a28-a093-11ec-a3a2-370b99bd241b.html LEARN ABOUT DEVICETALKS BOSTON https://gateway.on24.com/wcc/eh/2927718/lp/3691568/were-back-an-insiders-look-into-bringing-back-a-better-devicetalks-boston SIGN UP to try to present at DeviceTalks Boston though the MedTech Innovator Program https://medtechinnovator.org/apply/

We drill down on diagnostics – including COVID-19 testing – with Dave Hickey, newly promoted executive vice president and president of the life sciences segment of BD and Brooke Story, who took over his post as worldwide president of integrated diagnostic solutions. How did BD handle the crushing demand for at-home tests and where is diagnostics headed in the future. Paul Grand, CEO of Medtech Innovator, sits in with Chris Newmarker and Tom Salemi on this week's Newmarker's Newsmakers. He also delivers some important deadlines for medical device startups. This week's Newsmakers include Medtronic, Edwards Lifesciences, Distal Motion, Respironics and ZimVie. Find out more about Medtech Innovator at MedtechInnovator.org. Register for DeviceTalks at devicetalks.com. Use the discount code mentioned in this episode! Subscribe to this podcast on any major podcast channel.

Paul Grand is the CEO of Medtech Innovator which is an accelerator for startups in the medical technology space. It has been going for many years and the companies that they select to go through the 4 month process have gone on to be very successful. Apply for this year's cohort, deadline January 31st https://medtechinnovator.org/apply/  Top 3 Takeaways: "MedTech innovator as an accelerator is the world's largest accelerator for medical technology" "1,800 companies applied last year across all of our cohorts.  We accept around 4% of that." "Some of the benchmarks we've got: over 90 products in the market, $3.5 billion in follow on funding to our companies post-MedTech innovator, and we've had 21 acquisitions." 0:45 "Do you want to introduce yourself?" 3:00 "What is MedTech innovator for? Who is it for?" 6:00 "Is there exclusion criteria or is there some kind of a framework where certain companies would be better fits?" 9:30 Are there companies that would be too big for you? 10:30 "How do you find these companies?" 12:30 "How do you help find investment and how do you help people guide through this process?" 16:45 "What are some of your favorite success stories?" 22:15 Do busy CEOs have to drop everything in order to attend the 4 month workshop? 24:00 "What advice do you have for companies who want to get into Medtech Innovator?" 31:00 "Is there anything that we didn't mention that you wanted to talk about?"  

Paul Grand, MTI's CEO and Glenn Synder, Deloitte's Principle medtech practice leader discuss startups.

Gregory Montalbano speaks with Paul Grand who is the Founder and CEO of MedTech Innovator. Paul runs MedTech Innovator as a stand-alone non-profit which is also the largest accelerator of medical technology in the world. Together, Greg and Paul discuss the methods of mentoring and support offered to the entrepreneurial groups spanning medical device, digital health, and diagnostic applications. Paul will also outline the various MedTech Innovator industry as well as venture partner networks that support their members. Greg and Paul's discussions will also include what MedTech Innovator looks for in a startup and how they can apply to the MedTech Innovator programs. Lastly, this podcast will also cover new MedTech innovative initiatives and exciting breakthroughs that are expected on the horizon from the MedTech Innovator member network.

Welcome to another episode of forward. Paul Grand is former venture capitalist, and then started a non profit called MedTech Innovation which is the largest incubator and accelerator for any early stage medical technology and device company in the world. Paul is incredibly energetic, positive and has a phenomenal attitude which has allowed him to be successful as an entrepreneur, investor, and CEO of Non Profit.

In this episode, Giovanni and Paul discuss Medtech Innovator, how they add value to a start-up company, common errors he used to see in start-up companies, the mechanics of how Medtech Innovator works, how they prepare their companies for external capital and more. Paul Grand LinkedIn Medtech Innovator Website Giovanni Lauricella LinkedIn Project Medtech LinkedIn Project Medtech Website

In this episode, Giovanni and Paul discuss Medtech Innovator, how they add value to a start-up company, common errors he used to see in start-up companies, the mechanics of how Medtech Innovator works, how they prepare their companies for external capital and more. Paul Grand LinkedIn Medtech Innovator Website Giovanni Lauricella LinkedIn Project Medtech LinkedIn Project Medtech Website

Welcome to Outcomes Rocket MedTech, a podcast created to share the mindset and perspective of innovators and different stakeholders, get to know their founding stories, learn their unique challenges, and understand the value proposition of their products. In this episode, Paul Grand welcomes you to the podcast and shares excitement in bringing you closer to the entrepreneurs. His goal is to help you understand the journey of innovators as they try to solve healthcare problems. Paul invites you to listen, join the conversation and engage interactively to bring innovators to the people who need to know about them and vice versa. Click this link to the show notes, transcript, and resources: outcomesrocket.health

In this episode, we are thrilled to host Paul Grand, the CEO of MedTech Innovator, and Anna Lisa Somera, CEO of Rhaeos. They are in the podcast to talk about 2020’s MedTech Innovator Awards and how MedTech helps innovative companies leveraging technology to change the lives of their patients. Ms. Somera the 2020 Grand Winner. She shares how her company, Rhaeos, is developing a non-invasive wearable sensor to monitor the shunt among patients wearing hydrocephalus. Paul and Anna Lisa discussed the benefits of having the support of MedTech and how it has helped form connections with other healthcare leaders. Paul invites all med tech companies to join this year’s MedTech Innovator. It might be your turn to win the grand prize this year, so tune in to my interview with Paul and Anna Lisa to learn more.

In this episode with Paul Grand, CEO of Med Tech Innovator, we cover the importance of having a strategy and network that allows you to learn about innovation in the industry. His company has created the ultimate eco-system for start-ups, scale-ups and established businesses to collaborate and grow the overall impactful innovation we see in healthcare. I know you'll enjoy the conversation. To learn more about MedTechInnovator and get the full transcript visit https://outcomesrocket.health/medtechpaul/2020/06/

In this COVID-19 Series podcast, I host my good friend, Paul Grand, Founder and CEO of MedTech Innovator. He invites you to attend a live-stream event with 16 companies pitching their solutions to COVID-19 challenges. From diagnostics to remote monitoring, you may find something that hits the mark for your needs or interests. The event is free of charge and will also be available after the live-stream date so be sure to check it out! When: April 29th at 10:30am EST (a 45-minute meeting with live pitches) Where: https://medtechinnovator.org/covid-19/ For more COVID19 solutions visit: https://outcomesrocket.health/covid19/

DeviceTalks Weekly: Ep.5 –What impact is COVID-19 having on start-ups? Raising capital for start-up is never easy. Try doing it during a pandemic. In this week’s DeviceTalks Weekly, we’ll try to help entrepreneurs by talking with two guests who are committed to helping start-ups find the funding they need. Paul Grand, founder and CEO of MedTech Innovator, explains how he’s working to keep start-ups connected to capital. His popular MedTech Innovator program is adapting to the times and creating new ways for start-ups to get in front of investors. We’ll also talk with Shai Policker, CEO at MEDX Xcelerator, an incubator backed by Boston Scientific, Intellectual Ventures and others. Based in Israel, MEDX is moving forward and interested in investing capital in start-ups worldwide. Co-host Chris Newmarker, executive editor, life sciences, for WTWH Media, also updates us on what articles are drawing the most interest on MassDevice and Medical Design and Outsourcing. Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.

Interview with Paul Grand, founder and CEO of the MedTech Innovator program. In this interview Paul shares his experience and insights on the following: -How he get started in the innovation business -His "Why" for starting and the MedTech Innovator -Trends in HealthTech Investing and Global differences -What the MedTech Innovator is really all about Paul is a great example of someone who is making a difference.

This article is a collaboration between WNYC, ProPublica and The New Yorker. In the spring of 2012, Donald Trump’s two eldest children, Ivanka Trump and Donald Trump Jr., found themselves in a precarious legal position. For two years, prosecutors in the Manhattan District Attorney’s office had been building a criminal case against them for misleading prospective buyers of units in the Trump SoHo, a hotel and condo development that was failing to sell. Despite the best efforts of the siblings’ defense team, the case had not gone away. An indictment seemed like a real possibility. The evidence included emails from the Trumps making clear that they were aware they were using inflated figures about how well the condos were selling to lure buyers. In one email, according to four people who have seen it, the Trumps discussed how to coordinate false information they had given to prospective buyers. In another, according to a person who read the emails, they worried that a reporter might be onto them. In yet another, Donald, Jr. spoke reassuringly to a broker who was concerned about the false statements, saying that nobody would ever find out, because only people on the email chain or in the Trump Organization knew about the deception, according to a person who saw the email. There was “no doubt” that the Trump children “approved, knew of, agreed to, and intentionally inflated the numbers to make more sales,” one person who saw the emails told us. “They knew it was wrong.” In 2010, when the Major Economic Crimes Bureau of the D.A.’s office opened an investigation of the siblings, the Trump Organization had hired several top New York criminal defense lawyers to represent Donald, Jr. and Ivanka. These attorneys had met with prosecutors in the bureau several times. They conceded that their clients had made exaggerated claims, but argued that the overstatements didn’t amount to criminal misconduct. Still, the case dragged on. In a meeting with the defense team, Donald Trump, Sr., expressed frustration that the investigation had not been closed. Soon after, his longtime personal lawyer, Marc Kasowitz entered the case. Kasowitz, who by then had been the elder Donald Trump’s attorney for a decade, is primarily a civil litigator with little experience in criminal matters. But in 2012, Kasowitz donated $25,000 to the re-election campaign of Manhattan district attorney Cyrus Vance, Jr., making Kasowitz one of Vance’s largest donors. Kasowitz decided to bypass the lower-level prosecutors and went directly to Vance to ask that the investigation be dropped. On May 16, 2012, Kasowitz visited Vance’s office at One Hogan Place in downtown Manhattan — a faded edifice made famous by the television show, “Law & Order.” Dan Alonso, the chief assistant district attorney, and Adam Kaufmann, the chief of the investigative division, were also at the meeting, but no one from the Major Economic Crimes Bureau attended. Kasowitz did not introduce any new arguments or facts during his session. He simply repeated the arguments that the other defense lawyers had been making for months. Ultimately, Vance overruled his own prosecutors. Three months after the meeting, he told them to drop the case. Kasowitz subsequently boasted to colleagues about representing the Trump children, according to two people. He said that the case was “really dangerous,” one person said, and that it was “amazing I got them off.” (Kasowitz denied making such a statement.) Vance defended his decision. “I did not at the time believe beyond a reasonable doubt that a crime had been committed,” he told us. “I had to make a call and I made the call, and I think I made the right call.” Just before the 2012 meeting, Vance’s campaign had returned Kasowitz’s $25,000 contribution, in keeping with what Vance describes as standard practice when a donor has a case before his office. Kasowitz “had no influence and his contributions had no influence whatsoever on my decision-making in the case,” Vance said. But less than six months after the D.A.’s office dropped the case, Kasowitz made an even larger donation to Vance’s campaign, and helped raise more from others—eventually, a total of more than $50,000. After being asked about these donations as part of the reporting for this article—more than four years after the fact—Vance said he now plans to give back Kasowitz’s second contribution, too. “I don’t want the money to be a millstone around anybody’s neck, including the office’s,” he said. Kasowitz told us his donations to Vance were unrelated to the case. “I donated to Cy Vance’s campaign because I was and remain extremely impressed by him as a person of impeccable integrity, as a brilliant lawyer and as a public servant with creative ideas and tremendous ability,” Kasowitz wrote in an emailed statement. “I have never made a contribution to anyone’s campaign, including Cy Vance’s, as a ‘quid-pro-quo’ for anything.” Last year, The New York Times reported the existence of the criminal investigation into the Trump SoHo project. But the prosecutor’s focus on Ivanka and Donald, Jr. and the email evidence against them, as well as Kasowitz’s involvement, and Vance’s decision to overrule his prosecutors, had not been previously made public. This account is based on interviews with 20 sources familiar with the investigation, court records, and other public documents. We were not able to review copies of the emails that were the focal point of the inquiry. We are relying on the accounts of multiple individuals who have seen them. Requests for interviews with Ivanka Trump and Donald Trump, Jr., were referred to Alan Garten, the chief legal officer of the Trump Organization. In an emailed response, Garten did not address a list of questions about the criminal case. Instead, he quoted the company’s filings in civil litigation relating to the Trump SoHo, which described complaints as “a simple case of buyers’ remorse.” But even a lawyer in the Trump camp acknowledges that the way the case was resolved was unusual. “Dropping the case was reasonable,” said Paul Grand, a partner at Morvillo Abramowitz who was part of the Trump SoHo defense team. “The manner in which it was accomplished is curious.” Grand, who was a partner of Vance’s when the district attorney was in private practice, said he did not believe that the D.A.’s office had evidence of criminal misconduct by the Trump children. But the meeting between Vance and Kasowitz “didn’t have an air you’d like,” he said. “If you and I were district attorney and you knew that a subject of an investigation was represented by two or three well-thought-of lawyers in town, and all of a sudden someone who was a contributor to your campaign showed up on your doorstep, and the regular lawyers are nowhere to be seen, you’d think about how you’d want to proceed.” [Have a tip about this story? Click here to share information with WNYC and our reporting partners ProPublica and The New Yorker.] In June 2006, during the season finale of “The Apprentice,” Donald Trump, Sr. unveiled the Trump SoHo as a visionary project. The luxury development was intended to mark the ascension of Ivanka and Donald, Jr.—then 24 and 28 years old, respectively—as full players in the Trump empire. They signed the licensing deal alongside their father, and photographs of Ivanka were featured in the Trump SoHo’s advertising, under the tagline “Possess your own SoHo.” Their partners on the project included two Soviet-born businessmen, Felix Sater and Tevfik Arif, who ran the Bayrock Group, a real estate development firm. Sater had a history of running afoul of the law. In 1993, he was convicted of assault and spent about a year in prison for attacking a man with the stem of a margarita glass in a bar fight. In 1998, he pleaded guilty to one count of racketeering for his role in a $40 million securities fraud scheme. The Trump SoHo was beleaguered from the start: Named for one of Manhattan’s trendiest neighborhoods, the development wasn’t really in SoHo, but located just west of it, near the entrance ramp to the Holland Tunnel. Zoning laws wouldn’t allow a residential tower at the location, so the Trumps fell back on an alternative: a “condo-hotel,” in which buyers got a hotel room rather than an apartment, and were legally prohibited from staying there more than 120 nights per year. Worse, the high-priced condos hit the market in September 2007, just as the global economy began to crater in what became the largest financial crisis since the Great Depression. Business was slow, but the Trump family claimed the opposite. In April 2008, they said that 31 percent of the condos in the building had been purchased. Donald Jr. boasted to The Real Deal magazine that 55 percent of the units had been bought. In June 2008, Donald, Jr. and Ivanka, alongside their brother Eric, gathered the foreign press at Trump Tower in Manhattan, where Ivanka announced that 60 percent had been snapped up. “We’re in a very fortunate position,” she said, “where we have enough sales and now we are strategically targeting certain buyers.” None of that was true. According to a sworn affidavit by a Trump partner filed with the New York Attorney General’s office, by March of 2010, almost two years after the press conference, only 15.8 percent of units had been sold. This was more than a marketing problem. The deal hinged on selling at least 15 percent of the units. By law, the sales couldn’t close with anything less. The Trumps and their partners would have had to return the buyers’ down payments. Some buyers concluded that they’d been cheated. In August 2010, some sued the Trump Organization and others involved in the project in New York federal court. “This action seeks to redress the substantial and ongoing pattern of fraudulent misrepresentations and deceptive sales practices” by the Trumps and the other defendants, the suit charged. The plaintiffs argued that there’s a vast difference in value between a unit in a building that is fifteen percent sold and one that is sixty percent sold. Their complaint accused the sellers, including the Trumps, of “a consistent and concerted pattern of outright lies.” After the civil suit was filed, the Manhattan District Attorney’s office opened a criminal investigation. Prosecutors are often wary of getting involved in a dispute between wealthy litigants. But in this instance, according to a person familiar with their thinking, the lawyers in the Major Economic Crimes Bureau quickly concluded that there was enough to warrant an investigation. They believed that Ivanka and Donald, Jr., might have violated the Martin Act, a New York statute that bans any false statement in conjunction with the sale of a security or real estate. Prosecutors also saw potential fraud and larceny charges, applying a legal theory that, by overstating the number of units sold, the Trump were falsely inflating their value and, in effect, cheating unsuspecting condo buyers. Peirce Moser, an assistant district attorney known for his methodical, comprehensive investigations, soon took over the case. “He is not a cowboy,” Marc Scholl, who spent almost forty years as a prosecutor in the district attorney’s office, said. “He is certainly not out to make headlines for himself or to advance himself.” On the other side, the Trumps’ defense team included Gary Naftalis and David Frankel, of the law firm Kramer Levin; Paul Grand represented one of the real estate brokers who had worked with the Trumps. As the investigation progressed, Vance suffered an embarrassing setback in one of his highest profile cases. In the summer of 2011, his office had abandoned a sexual-assault case against the former managing director of the International Monetary Fund, Dominique Strauss-Kahn. Vance, who was pummeled in the press afterward, denied in his interview with us that the case made him reluctant to take on another prominent defendant. A few months later, on Jan. 11, 2012, Marc Kasowitz contributed $25,000 to Vance’s campaign, unbeknownst to prosecutors in the Major Economic Crimes Bureau, who continued their work. Moser was particularly focused on email correspondence, according to seven people familiar with the case. The prosecutors began considering impaneling a special grand jury, according to a person familiar with the investigation. That would have represented a significant escalation in the case, because it is often a prelude to indictments. With a grand jury in place, defense lawyers knew the risk of indictment was high. The defense team offered a deal to stave off this possibility, floating the possibility of a settlement of some kind, including a deferred prosecution agreement, which would have meant the corporate equivalent of probation for the Trump Organization. With the investigation appearing to gather momentum, Naftalis and Grand, who had already met with the prosecutors twice, began to step up their campaign against the case. Grand calls this the “internal appellate process.” Particularly when well-heeled or high-profile defendants are involved, there can be a multi-month advocacy process that slowly makes its way up the hierarchy inside the Manhattan D.A.’s office. Grand and Naftalis decided that it would be unwise to go over the heads of the staff prosecutors. Instead, on April 18, 2012, they sent a letter to Adam Kaufmann, then chief of the investigative division (he’s now in private practice), outlining their arguments. The next day, the defense lawyers met with Moser, Kaufmann, and others from the prosecution team. The defense team acknowledged that the Trumps made some exaggerated statements in order to sell the units. But this was mere “puffery”— harmless exaggeration. Such language, they contended, didn’t amount to criminal conduct. The Trumps weren’t selling useless swampland in Florida. The condos existed. And the buyers’ money was in escrow the entire time. The defense lawyers argued that bringing such a case to trial would be wasteful and that resources would be better spent on more serious offenses. As Grand put it to us during our recent interview, “I guess in a world that is completely pure and where there is no deviation between propriety and the law, that kind of exaggeration and deliberately concentrated exaggeration can be pursued. But is that the kind of criminal law enforcement the D.A. should be doing?” Moser’s answer seemed to be “yes,” and he found support among his supervisors. Moser had prepared an elaborate PowerPoint presentation, featuring dozens of emails that prosecutors believed showed that Ivanka and Donald, Jr. had repeatedly lied to buyers. “You couldn’t have had a better email trail,” a person familiar with the investigation told us. At the meeting, Kaufmann peppered the defense team with questions, at one point raising his voice, according to a person who was there. “I believed in the case,” Kaufmann told us, though he declined to discuss the evidence. “But believing in the case doesn’t mean we had reached the point when [I had] settled on what should happen with the case.” *** White-collar criminal cases are often challenging to bring because of their complexity. And, by the time of the April meeting, prosecutors knew that they faced another impediment, this one created by legal maneuvers in the Trumps’ civil case. Five months earlier, the Trumps and their partners had reached a settlement with the disgruntled buyers. The defendants agreed to return 90 percent of the buyers’ deposits, plus their attorneys’ fees. But they extracted a rare concession in return: The plaintiffs agreed not to cooperate with prosecutors unless they were subpoenaed. (Garten, the Trump Organization’s chief legal officer, noted that the settlement terms were confidential and declined to comment on them.) Adam Leitman Bailey, the attorney for the buyers, had been helping prosecutors. Now he provided aid to the Trumps, writing a letter to the district attorney that stated: “We acknowledge that the Defendants have not violated the criminal laws of the State of New York or the United States.” In our interview with Vance, he said he had never before seen a letter where plaintiffs in a civil case asserted that no crime had been committed. “I don’t think I’d ever received a letter like it,” Vance said. He calls it a “significant and important” communication. Certainly, prosecutors could subpoena the buyers of Trump condos. But they feared the witnesses would undercut the criminal case by claiming they weren’t victims of a fraud. Still, Moser, backed by his supervisors, persisted. “Peirce believed in his case,” Grand said. “We did not succeed in talking him out of it and didn’t succeed in talking one or two levels above him into dropping the case.” *** Finally, in the spring of 2012, Kasowitz joined the case. His involvement “came from out of the blue,” Grand told us. He and the other lawyers assumed Kasowitz intervened at the request of Donald Trump, Sr. In early May 2012, Kasowitz asked to see the District Attorney. Vance told us such meetings aren’t unusual — but his investigations chief at the time, Kaufmann, characterized Kasowitz’s request as “a little premature.” The Trump lawyer was going over the heads of everyone who had been working on the case. The gathering, on May 16, lasted 20 to 30 minutes, according to Vance. Kasowitz repeated the arguments the defense team had made before. Afterwards, Kasowitz didn’t seem to think his clients were in the clear. On August 1, he suggested a settlement, proposing that the Trump Organization would not admit to wrongdoing but would agree not to mislead people in the future and would submit to outside monitoring. The offer proved unnecessary. Two days later, on August 3, 2012, Moser called the Trumps’ defense attorneys and told them prosecutors were dropping the investigation. (Moser, who  still works for Vance, now as senior investigative counsel, did not respond to requests for an interview made over multiple months. Shortly before this article was published, he sent an email stating that Vance’s ultimate decision in the case “was not unreasonable” and that throughout the process, the D.A. asked “smart questions” and expressed “reasonable skepticism.”) In his interview, Vance defended his decision to drop the case with no conditions, even after Kasowitz offered a deal. “This started as a civil case,” Vance said. “It was settled as a civil case with a statement by the purchasers of luxury properties that they weren’t victims. And at the end of the day, I felt if we were not going to charge criminally, we should leave it as a civil case in the posture in which it came to us.” In September 2012, within weeks of the case being resolved, Kasowitz contacted Vance’s campaign about hosting a fundraiser, according to a spokesperson for the campaign. Kasowitz held the event that January. He personally donated almost $32,000 to Vance’s campaign, and 20 of his law firm’s partners and employees kicked in at least another $9,000. Then, in October 2013, as Election Day approached, he hosted a breakfast —“Republicans for Cy Vance” — which raised an additional $9,000. Vance defended his decision to accept the money Kasowitz sent his way. “We did the right thing,” he said, referring to the decision to drop the case. “Another five and a half months go by. Marc Kasowitz has no matter pending before the office for the Trumps or anybody else. It’s 2013 and it’s an election—and I welcome his support.” Vance noted that New York law allowed him to accept such a contribution. Still, he now intends to return the money to Kasowitz. Ivanka Trump is now an adviser to the President, with an office in the West Wing. Donald, Jr., is running much of the family empire while his father is in the White House. Kasowitz attained national prominence when he was retained to represent the president in the Russia investigation, only to be supplanted as lead counsel. Vance is running unopposed for reelection in November. The Trump SoHo went into foreclosure in 2014 and was taken over by a creditor. Only a hundred and twenty-eight of the three hundred and ninety-one units in the building have sold. That comes out to around thirty-three percent. Derek Kravitz and Leora Smith of ProPublica contributed reporting to this article, as did Keenan Chen, Alex Mierjeski, Inti Pacheco and Manuela Andreoni of Columbia Journalism Investigations. This article is a collaboration between WNYC, ProPublica and The New Yorker. 

In this dual episode of Inside the Founder's Studio, CTC visits with Marcel LeBrun, co-founder of Radian6. He talks through the founder process in Atlantic Canada and what it meant to be removed from Silicon Valley. We also talk with Paul Grand of RCT about medtech investing and RCT's Medtech Innovator challenge. Paul tells us about the challenge process and connecting medtech entrepreneurs with industry leaders.

Le docteur Paul Grand’Maison a exposé devant quelques centaines de personnes les dernières années, derniers mois et dernières minutes de la vie de son épouse. ...